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Background: To evaluate whether a fermented dairy drink containing the probiotic strain Lactobacillus casei DN-114 001 could
reduce the incidence of common infectious diseases (CIDs) and the change of behavior because of illness in children.
Subjects/Methods: We conducted a double-blinded, randomized, placebo-controlled allocation concealment clinical trial in
the Washington, DC metropolitan area. Participants were 638 children 3–6 years old in daycare/schools. The intervention was a
fermented dairy drink containing a specific probiotic strain or matching placebo with no live cultures for 90 consecutive days.
Two primary outcomes were assessed: incidence of CIDs and change of behavior because of illness (both assessed by parental
report).
Results: The rate of change of behavior because of illness was similar among active and control groups. However, the incidence
rate for CIDs in the active group (0.0782) is 19% lower than that of the control group (0.0986) (incidence rate ratio¼0.81, 95%
CI: 0.65, 099) P¼0.046.
Conclusions: Daily intake of a fermented dairy drink containing the probiotic strain L. casei DN-114 001 showed some promise
in reducing overall incidence of illness, but was primarily driven by gastrointestinal infections and there were no differences in
change of behavior.
European Journal of Clinical Nutrition (2010) 64, 669–677; doi:10.1038/ejcn.2010.65; published online 19 May 2010
Keywords: probiotics; clinical trial; infections; functional foods
Introduction
Common infectious diseases (CIDs) cause discomfort to
individuals and result in economic losses because of missed
days from work, seeking of medical care, and medication
costs (Feeney et al., 1998; Greenberg, 2002). Daycare
centers and schools are ideal places for the transmission
of respiratory infections as well as childhood diarrhea,
often resulting in many missed days of both daycare and
parental work (Fleming et al., 1987; Cordell et al., 1997;
Dales et al., 2004). Illnesses related to daycare centers
have been estimated to cost $1.8 billion per year in the
United States (Haskins, 1989). Children in daycare centers
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www.nature.com/ejcnhave shown to have more outpatient doctor visits, emer-
gency room visits, and increased usage of prescription
medicines than children not in daycare (Silverstein et al.,
2003).
Probiotics are live microorganisms, which when adminis-
tered in adequate amounts confer a health benefit (FAO/
WHO, 2001). In the past few years, scientific and commercial
interest in probiotics has grown rapidly as these micro-
organisms have shown potential benefits, primarily in
prevention, in health conditions such as diarrhea, necro-
tizing enterocolitis, and allergies (Vanderhoof et al., 1999;
Kalliomaki et al., 2001; Rosenfeldt et al., 2002; Mastrandrea
et al., 2004; Lin et al., 2005, 2009).
However, there is need for controlled clinical studies
evaluating the health benefits of probiotic foods containing
well-defined probiotic strains. The effects of one product are
not extrapolative of another, and may also depend on the
amount ingested and the pattern of consumption. In
addition, the outcomes measured in probiotic trials need to
properly reflect the outcomes of interested individuals
consuming the probiotics, if the results are going to impact
public health (Tunis et al., 2003; Glasgow et al., 2005).
Our overall aim was to study health benefits of a well-
characterized probiotic food that is readily available to
consumers—DanActive (also referred to as Actimel), a
probiotic dairy drink, available in grocery stores in many
countries worldwide. Earlier published clinical trials have
found this product to decrease incidence and duration of
diarrhea and allergic rhinitis in infants and children (Pedone
et al., 1999, 2000; Agarwal and Bhasin, 2002; Giovannini
et al., 2007). Furthermore, clinical studies conducted on
DanActive to assess the survival of the Lactobacillus (L.) casei
through the digestive tract have shown high survivable
numbers from the stools of subjects consuming the product
(Guerin-Danan et al., 1998; Oozeer et al., 2002, 2006; Rochet
et al., 2008). Survival of probiotic strains through intestinal
transit is considered an important biomarker for potential
functionality in the intestinal tract.
The objective of this study was to investigate the beneficial
effects of this probiotic fermented product on common
infections by conducting a large-scale study on children
attending daycare/schools. The outcomes of this clinical
study are patient-oriented, not surrogate, end points
(Fleming and DeMets, 1996; Shaughnessy and Slawson,
1997, 2003). We hypothesized that, because of high levels
of the probiotic in the dairy drink, children in daycare/
school who received the active drink would have reduced
overall illness and thus reduced changes in activity because
of illness as assessed by their parents.
Materials and methods
Study design
A double-blinded, randomized, placebo-controlled, patient-
oriented trial was conducted. Participants consumed one
active or control drink for 90 consecutive days and were
followed weekly during consumption. The Georgetown
University IRB, in Washington, DC, approved all aspects of
the trial and participants’ parents signed informed consent.
An independent Data and Safety Monitoring Board met and
reviewed data at 25, 50, and 75% completion and reviewed
all adverse events (AEs).
In addition to weekly assessments conducted by phone
interviews between clinical coordinators and parents,
parents were provided with daily calendars (diary). Diary
data provided secondary assessment. All data were double
entered into a Microsoft Access database developed by the
independent Data Management Coordinating Center.
Participants
Healthy children between the age of 3 and 6 years attending
daycare center/school 5 days a week in Washington, DC area
were recruited into the study. Exclusion criteria were taking
any regular medicines at initiation of study, lactose intole-
rance, allergy to strawberry, inability of a parent to speak
English or Spanish, active respiratory or gastrointestinal
infection, or chronic disease. Participants were also excluded
for consuming other probiotic foods or supplements.
Randomization
The randomization scheme was generated using SAS
software by data managers, who had no participant contact.
Households were randomized in a 1:1 ratio to receive either
the active or control drink, using a block size of 12. Children
in the same household were assigned to the same drink
group. Once eligibility criteria were met, the participant was
randomized to one of the two groups, study identification
was generated and a number from 0 to 9 was assigned.
Participants were enrolled by research assistants.
Interventions
The active drink was strawberry-flavored DanActive, a
fermented probiotic dairy drink, which has been commer-
cially available since 1994 in Europe, under the commercial
name ‘Actimel’ and is currently available in the US market.
The drink contains the probiotic strain L. casei DN-114 001/
CNCM I-1518 (also named Lactobacillus paracasei subsp.
paracasei after the current nomenclature) combined with two
cultures commonly used in yogurt, Streptococcus thermophilus
and Lactobacillus bulgaricus. As the purpose of this study was
to evaluate the effects of this specific product as a whole,
the control product used was a sweetened, flavored non-
fermented acidified dairy drink. Subjects were allocated one
bottle per day of either drink. Microbiological content was
verified by an independent laboratory, The National Food
Laboratory, Inc. (Dublin, CA, USA). The microbiological
composition of the active drink at the end of shelf life met
targets of 1 10
8cfu/g of L. casei DN-114 001. The yogurt
starter, symbiotic cultures, S. thermophilus, and L. bulgaricus
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7cfu/g.
The Placebo was a sweetened, flavored non-fermented
acidified dairy drink without the active components of the
tested product. See Table 1 for nutritional content.
Blinding
Through masking and use of 10 different numbers, 0
through 9, it was impossible for research personnel to adjust
randomization or deduce what group participants were
assigned. In addition, parents were told that the trial was
investigating a probiotic drink, but they were never alerted
to the actual product. The appearance, taste, nutritional
composition (proteins, carbohydrates, lipids, and energy),
and packaging (200g bottles) of the active and control
products were identical to ensure that neither subjects, their
parents, nor researchers knew the identity of the study
samples. All of these measures led to successful true
allocation concealment and proper blinding.
Outcome measures
The study was designed for two primary outcomes: (1) the
change of behavior because of illness as assessed by parents
and (2) the rate of CIDs. To assess behavior changes, parents
were specifically asked, ‘In the past week, has your child had
an illness that resulted in change in activity, such as missed
school, birthday party, soccer game, etc.? ‘Change in activity’
refers to all activities, not just structured ones.’ All assess-
ments were performed by parents to be consistent with
a community trial of a commercial product.
CID was categorized based on the reported health-related
symptoms that parents relayed on a weekly basis to the
research personnel. CID was separated into three categories
of infections, a priori to review of data: upper respiratory tract
infections, which included ear infections, sinusitis, strepto-
coccal pharyngitis, non-strep pharyngitis, nasal discharge,
and laryngitis; lower respiratory tract infections, which
included pneumonia, influenza, coughs, and breathing
problems; and gastrointestinal tract infections (GITI), which
included gastroenteritis, diarrhea, nausea, and vomiting.
Diarrhea was not clinically defined, but parent reported.
The overall CID at each follow-up visit (with period covering
1 week) could be p3.
Secondary outcomes included absences from daycare or
school because of illness and missed parental work because
of child being ill, days with diarrhea, vomiting, stomach
pain, constipation, runny nose, cough, decreasing appetite,
fever, medication usage, or rash. AEs were collected on the
weekly follow-up or parents had a 24-h phone number to call
and report any AEs. All AEs were also included in illness
reports. AEs were determined by the parent or their personal
physician if they believed that any event was potentially
related to the drink. Serious AEs were defined as any
incidences of death, life-threatening event, hospitalization,
prolongation of hospital stay, or event resulting in perma-
nent disability.
Statistical analysis
The estimates used to conduct the sample size calculations
were obtained from two earlier probiotic studies and a 90-
day trial was selected based on rate of earlier reported
infections. In addition, we choose 3 months over the colder
period of the year because of an increase in respiratory illness
(Hatakka et al., 2001; Weizman et al., 2005). The sample size
calculations considered in this study are based on a cluster
sampling approach that accounts for multiple children
enrolled into the study from the same household. Children
in the same household are not independent; hence, the
power calculations and the analysis were adjusted for the loss
of power because of randomizing by these clusters. To
calculate the adjusted sample size, we used an estimate of
0.1 as the intra-class correlation between household, the
design effect was 1.05, and the adjusted sample size required
was 638 accounting for 20% effect size and a 20% dropout.
The number of households required to provide this sample
was around 426 with the assumption that average household
size is 1.5. This sample size was based on setting statistical
significance at 0.05 and 80% power. Missing data were
replaced by the Last Value Carried Forward method using the
last post-baseline value for one subject at the earlier time
when appropriate.
Statisticians masked to the group allocation conducted
statistical analyses. Furthermore, all research personnel were
masked while examining initial data. Baseline demographics
were compared between the groups using independent t-test
for continuous variables and w
2 test for categorical variables.
All analyses of primary and secondary analyses of outcomes
were conducted on an intention-to-treat basis. Incidence rate
ratios were calculated using the number of events divided
by number of days in study. The mixed model was used to
adjust for clustered observations from the same household.
For binary outcomes, the generalized non-linear mixed
model was used; and for continuous outcomes, the general-
ized linear mixed model was used. Adjustments were made
based on age and number of drinks consumed. A P-value
of o0.05 was considered to indicate statistical significance.
Table 1 Nutritional facts for both drinks
Cholesterol (mg) 10.18
Calcium (mg) 200
Potassium (mg) 266
Sodium (mg) 85
Total fat (g) 3
Protein (g) 6
Total carbohydrates (g) 27
Total added sugars (g) 19
Calories kcals/200g 161
Participants consumed 200ml/day.
Nutritional facts are per 200ml.
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Inc., Cary, NC, USA) and Intercooled Stata 9.2 for Windows
(StataCorp LP, College Station, TX, USA) were used to run the
analyses.
Results
Recruitment, enrollment, and participant flow
During the 5 months of enrollment from 27 September 2006
until 22 February 2007, 872 messages were left on the
recruitment line (Figure 1). Eligibility could not be assessed
for 127 families because of unsuccessful attempts to contact
families. Thus, 745 families were assessed for eligibility, with
64 not meeting inclusion criteria. Six hundred thirty-eight
participants were enrolled from these callers, or 73% of the
original families who left messages on the recruitment line,
314 were allocated into the active participant group, and
324 into the control group with 250 families in both groups
(Figure 1).
Baseline demographics
There were no major differences with respect to any of the
baseline characteristics between the two groups (Table 2).
Both groups had 250 families; the active group had 193
families with 1 child, 51 with 2 children, and 6 with 3 or
more children; the control group had 184 families with
1 child, 59 with 2 children, and 7 with 3 or more children.
The majority of the children spent at least 30h per week
in daycare/school at baseline. On a 10-point Likert scale
ranking overall health, both groups were reported as 9.2
Figure 1 Participant flow chart.
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clinical trials, the majority of participants were white with
high family incomes, but the study population also consisted
of 18% Hispanics (participant’s parents classified race and
ethnicity), and 20% of families had annual incomes
o$30000. In addition, 17% of the interviews were con-
ducted in Spanish (data not shown).
Compliance
The number of drinks consumed per week differed between
the active (6.5 drinks per week) and control (6.1 drinks
per week) groups (P¼0.004). However, the difference in
compliance between those who predicted correctly what
drink their child had consumed and those who predicted
incorrectly in the active group was not significant (P¼0.321).
Similarly, the difference in compliance between those who
predicted correctly and those who predicted incorrectly in the
control group was not significant (P¼0.967).
Primary outcomes
As discussed in Materials and methods section, the study was
a priori arranged for two primary outcomes (Table 3). The
primary outcome, rate of days with change in activity
because of illness per 100 person day, was similar in the
active and control groups (active¼2.30, control¼2.27,
P¼0.91). However, the incidence rate for CIDs in the active
group (0.0782) was 19% lower than in the control group
(0.0986), representing a statistically significant difference in
the active group (incidence rate ratio¼0.81, 95% CI: 0.65,
0.99 P¼0.046). Further subdivision by the three compo-
nents of CID (upper respiratory tract infections, lower
respiratory tract infections, GITI) showed the primary cause
of lower overall incidence of GITI infections followed by
upper respiratory tract infections. The incidence rate for GITI
in the active group (0.012) was 24% lower than in the
control group (0.016), (incidence rate ratio¼0.76, 95% CI:
0.58, 0.99, P¼0.042). The incidence rate for upper respira-
tory tract infections in the active group was 0.027, which was
18% lower than in the control group (0.033) (incidence rate
ratio¼0.82, 95% CI: 0.68, 0.99, P¼0.036). The incidence
rate for lower respiratory tract infections in the active group
was 0.027, which is 2% lower than in the control group
(0.028) (incidence rate ratio¼0.98, 95% CI: 0.82, 1.18,
P¼0.829). Although we cluster randomized by households,
we did not randomize per daycare/school as participants
were from 358 different daycare/schools. However, analysis
showed no differences in primary outcomes per daycare
(data not shown).
Secondary outcomes
There were no statistically significant differences in any of
the secondary outcomes shown in Table 3, such as partici-
pant missed daycare/school or parental missed work between
Table 2 Participant demographics
Active N (%) Control N (%)
Number of subjects 314 324
Gender
Male 157 (50.0%) 172 (53.1%)
Female 157 (50.0%) 152 (46.9%)
Age (years)
Mean (s.d.) 4.86 (þ1.12) 4.94 (þ1.13)
Hours/week in school
o15h 6 (1.9%) 5 (1.5%)
15–20h 33 (10.5%) 44 (13.6%)
21–30h 62 (19.7%) 47 (14.5%)
31–40h 143 (45.5%) 159 (49.1%)
440h 70 (22.3%) 69 (21.3%)
Race (biological mother)
Asian (M) 26 (8.3%) 18 (5.6%)
American Indian or
Alaska Native (M)
8 (2.5%) 15 (4.6%)
Black or African American (M) 70 (22.3%) 71 (21.9%)
Native Hawaiian or other
Pacific Islander (M)
1 (0.3%) 2 (0.6%)
White (M) 192 (61.1%) 195 (60.2%)
Other (M) 16 (5.1%) 20 (6.2%)
Race (biological father)
Asian (F) 26 (8.3%) 11 (3.4%)
American Indian or
Alaska Native (F)
6 (1.9%) 18 (5.6%)
Black or African American (F) 67 (21.3%) 70 (21.6%)
Native Hawaiian or other
Pacific Islander (F)
3 (1.0%) 2 (0.6%)
White (F) 174 (55.4%) 194 (59.9%)
Other (F) 30 (9.6%) 27 (8.3%)
Ethnicity (biological mother)
Hispanic or Latino (M) 52 (17.1%) 51 (15.8%)
Not hispanic or Latino (M) 252 (82.9%) 272 (84.2%)
Ethnicity (biological father)
Hispanic or Latino (F) 55 (18.3%) 59 (18.3%)
Not hispanic or Latino F) 245 (81.7%) 263 (81.7%)
Overall 300 322
Health insurance
No 8 (2.5%) 12 (3.7%)
Yes 306 (97.5%) 312 (96.3%)
Income
o$15000 9 (3.8%) 22 (9.0%)
$15000–$30000 34 (14.2%) 29 (11.9%)
$30001–$50000 26 (10.9%) 23 (9.4%)
$50001–$75000 29 (12.1%) 27 (11.1%)
$75001–$100000 46 (19.2%) 36 (14.8%)
4$100000 95 (39.7%) 107 (43.9%)
Overall health
a
Mean (s.d.) 9.2 (þ0.9) 9.2 (þ0.9)
Abbreviation: s.d., standard deviation.
aOn a scale of 1–10, how would you rate your child’s overall health in the past
week? 1¼very unhealthy, 10¼extremely healthy.
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medication use. In the active group, the mean number of
days a medicine used was 3.02 days versus 3.32 days in the
control group (Po0.0001). Furthermore, there was also a
significant statistical difference in antibiotics (N¼58 in
intervention and N¼69 for control, P¼0.002) and anti-
inflammatory (N¼77 in intervention and N¼97 in control,
P¼0.03) drug usage in the control group compared with the
active group, when used as a covariate in the primary
analysis model. However, the absolute numbers are not large
and we believe not clinically significant.
Additional analysis
In general, parents were more compliant with weekly follow-
up phone calls than with maintaining the diary. In the active
group, at days 30, 60, and 90, 84, 76, and 66% of parents
completed diaries compared with 82, 71, and 57% in the
control group, respectively. As expected, the parents who
were more compliant with the diary were slightly more
compliant ensuring that their children consumed the drinks.
The consumption rate in the active group was a mean of 6.6
drinks per week among those who completed the diary,
compared with 6.5 in the overall group, whereas control
consumption rates were 6.3 among those who completed the
diary compared with 6.1 overall. In addition, missed
participants’ days because of illness showed non-significant
24% difference in the active group (P¼0.08) and 33% less
parental missed work in the active group compared with
control (P¼0.22).
Figure 2 shows CIDs are differently distributed between
groups, with more outliers in the control group. Per protocol
analysis is not shown, but is similar for all outcomes. The
difference in CID subcategories is still significant, when
adjusting for multiple comparisons using Bonferroni’s
adjusted P-value of 0.025.
Adverse events
Global safety in the study was excellent as expected for a
study on a commercially available food using healthy
subjects. In the active group, 18 subjects had at least one
AE compared with 22 in the control group (Table 4). In
addition, one subject in the active group had a serious AEs
compared with two in the control group. The SAEs were all
hospitalizations that resolved spontaneously and believed
not related to study product. All participants recovered
within days without any subsequent sequelae.
Discussion
Yogurt and yogurt-like fermented milks are well established
and popular with children and parents. These products
provide live cultures to the diet and nutrition in the
form of protein, vitamins, and minerals. In addition, these
products are relatively inexpensive, widely available, and
easy to ingest. However, the value of the microbiological
components of yogurts containing only traditional live
cultures (S. thermophilus and L. bulgaricus) is generally
limited to improving lactose digestion in lactose malabsor-
bers. These two active starter cultures do not survive
intestinal transit in significant quantities and thus,
have limited ability to positively impact intestinal health.
This is the rationale behind many newer dairy products,
which contain supplemental probiotic bacteria believed
to survive the gastrointestinal tract. Unfortunately, vali-
dation of health effects of these products with meaningful
Table 3 Primary and secondary outcomes
Active Least squares
mean (s.e.)
Control Least squares
mean (s.e.)
P-value
Primary outcomes
Incidence rate of CID per 100 person day
a 7.8 (0.4) 9.8 (0.7) 0.046
Rate of days with change in activity because of illness per 100 person day
b 2.30 (0.21) 2.27 (0.21) 0.91
Secondary outcomes
Incidence rate of GITI per 100 person day
a 1.2 (0.10) 1.6 (0.15) 0.042
Incidence rate of URTI per 100 person day
a 2.7 (0.18) 3.3 (0.20) 0.036
Incidence rate of LRTI per 100 person day
a 2.7 (0.16) 2.8 (0.18) 0.829
Rate of vomiting per 100 person day 0.55 (0.08) 0.73 (0.08) 0.10
Rate of stomach pain per 100 person day 1.23 (0.21) 1.50 (0.21) 0.36
Rate of constipation per 100 person day 0.81 (0.18) 0.71 (0.18) 0.68
Rate of runny nose per 100 person day 7.88 (0.63) 8.65 (0.63) 0.39
Rate of cough per 100 person day 9.18 (0.63) 8.37 (0.63) 0.36
Rate of decreasing appetite per 100 person day 2.58 (0.31) 2.31 (0.31) 0.54
Rate of fever per 100 person day 1.34 (0.14) 1.34 (0.14) 0.99
Rate of rash per 100 person day 1.17 (0.23) 0.76 (0.23) 0.21
Abbreviations: CID, common infectious disease; GITI, gastrointestinal tract infections; LRTI, lower respiratory tract infections; URTI, upper respiratory tract infections.
aIncidence rate per 100 person day¼incidence rate per day 100.
bRate of days with change in activity because of illness¼number of days with change in activity/number of days in the study.
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lacking.
Our aims in this study were to examine whether children
who received a fermented milk containing the probiotic,
L. casei strain DN-114 001, and two traditional yogurt starters
would have reduced overall illness and have less change in
activity because of illness, as reported by their parents, than
the children receiving control product. Although, we have
mixed results, to our knowledge this is the largest probiotic
clinical trial conducted in the United States and provides
much needed data. One of the primary and most of the
secondary outcome measures were negative, and although
some of our positive findings are driven by a few individuals,
the reduction of GITI (24% lower than control) is a robust
outcome consistent with earlier probiotic research on this
product. There are many potential hypotheses as to why we
had mixed results in our study. Perhaps, it was easier for
parents to determine whether a child had a runny nose, ear
pain, or other symptom, but less clear if a young child’s
activity level was changed. Possibly, symptoms were suffi-
ciently obvious to report, but insufficient in severity to
result in a canceled activity. In addition, most of the positive
earlier research on this product has been with gastrointest-
inal symptoms (Pedone et al., 1999, 2000; Agarwal and
Bhasin, 2002; Giovannini et al., 2007; Hickson et al., 2007).
Our results are similar in that the drink has its greatest
impact in reducing GITI; however, this may impact overall
health, but not activity levels of young children. A recently
published manuscript examining the same intervention
found a significantly decreased duration of CID (P¼0.009)
in comparison with the control group in an elderly
population (Guillemard et al., 2010). Earlier conducted
preclinical studies provide hypotheses on mechanisms of
action and relevant information about the biological
plausibility of the observed clinical effects on CIDs in
human studies conducted with our intervention (Djouzi
et al., 1997; Guerin-Danan et al., 2001; Freitas et al., 2003;
Ingrassia et al., 2005; Medici et al., 2005; Parassol et al., 2005;
Tien et al., 2006; de Moreno de LeBlanc et al., 2008; Baba
et al., 2009).
Similar to primary outcomes, secondary outcomes showed
mixed results. The active group used statistically less
medicine, but this was of questionable clinical significance
as the absolute numbers were similar. In addition, there were
no differences among groups in outcomes such as missed
Figure 2 Distribution of subjects for cumulated number of CID during the study product consumption.
Table 4 Adverse events
Outcomes Active N (%) Control N (%)
314 (100%) 324 (100%)
Number of subjects with at least
one adverse event (AEs)
18 (5.73%) 22 (6.81%)
Diarrhea 6 3
Gas 1 0
Vomiting 0 3
Lack of appetite 0 3
Constipation 2 2
Hives 1 0
Rash 7 10
Other 5 9
Number of subjects with at least
one serious adverse event (SAEs)
a
12
aActive group SAE versus gastro-intestinal virus, participant evaluated in
emergency room and discharged, and control included an asthma attack
induced from pneumonia, and a viral infection requiring hospitalization
because of high fever.
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European Journal of Clinical Nutritionwork or daycare/school. A study by Hatakka et al. examined
the effects of the probiotic Lactobacillus rhamnosus GG on
children in daycare centers. Children in the L. rhamnosus GG
group showed a 16% decrease in absences from daycare
compared with control, and a significantly lower incidence
of respiratory infection (relative reduction 17%, absolute
reduction 9%) (Hatakka et al., 2001). Weizman et al. also
studied probiotics in daycare centers. They fed infants either
Bifidobacterium lactis Bb-12, Lactobacillus reuteri ATCC55730,
or control formula containing no added probiotic. The
control group had more days of febrile illness, increased
episodes of diarrhea, and increased absences from daycare
than the groups on the probiotic-fortified formulas
(Weizman et al., 2005). Our diary data did show participants
in the active group had a statistically insignificant 24%
decrease in daycare/school absences during the study period
and parents had a statistically insignificant 33% less missed
work in the active group compared with control during
the 90-day trial. It is likely that the reason these major
differences are not significant is due to the low number of
completed diaries and a larger study may have found
differences in activity levels. In addition, our study popula-
tion was much more diverse than these two studies and
many other more disease-oriented probiotic trials.
Our study has several limitations that need to be noted.
We intentionally did not include independent examinations
of children by physicians and instead relied on parental
report. We studied a functional food, not a medicinal
product; parents will thus feed their children without any
physician input and we felt it was best to assess it under
similar conditions. A limitation of this method is that some
of these assessments are subjective and vary by evaluator.
However, the large sample size and strict methodology
should result in equal assessments per group. In addition,
we enrolled generally healthy children from daycare/school
settings. It is possible if our source population was not as
healthy, we would have had different findings. Our overall
illness rate was less than we anticipated from earlier
literature and it was reported as a ‘mild’ winter for illness
in our recruitment area. Finally, compliance was measured
by self-report. However, we analyzed through intention to
treat, which is especially appropriate for a food product,
which is unlikely to be consumed in real life everyday
without missed servings.
Our randomized clinical trial shows that a fermented dairy
drink with a characterized probiotic strain holds promise,
but has limitations in promoting the health of children aged
3–6 years. The results of our clinical trial support the
effectiveness of this product with an important patient-
oriented outcome, CID, most specifically in gastrointestinal
illness. It is important to recognize that this trial studied a
specific probiotic strain, dose, and age group, and our
findings cannot be extrapolated for other strains or outcomes.
It is important that commercial products continue to be
independently studied, important patient-oriented outcomes
assessed, and subjected to high quality research techniques.
Conflict of interest
Drs Davis, Niborski, and Tondu were employees of the
Dannon Company during this trial. Dr Mary Ellen Sanders
consults for numerous probiotic companies including the
Dannon Company.
Acknowledgements
We thank the families who participated in this study;
Jennifer Foley Zaccagino, the administrator of this grant;
Greg Foster for creating and implementing the Data Manage-
ment Program and his biostatistical assistance; Dr Helaine
Resnick for her statistical input and early protocol develop-
ment; Shaunaugh Browning and the GCRC staff; Colleen
Varga, senior research assistant, and the research assistants,
A Degbo, M Ellestad, J Foster, J Gonzalez, K Herbin-Smith,
C Jackson, A McEwan, L Paster, R Sandler, D Simmons, I
Williams; Li Lu for her statistical support; the Data Safety
Monitoring Board, with Chair Dr Marie Diener-West and
members Drs Beth Barnet, Charles Mouton, and Nicole Ugel;
Cargo Transport, Inc. (Dulles, VA, USA), which provided
shipping logistics and delivery of study product; and Bartson’s
Child’s Play (Washington, DC, USA), which provided
age-appropriate compensation for the participating children.
This study was an investigator-initiated industry funded
study by The Dannon Company, Inc. The non-industry
authors developed the initial protocol, gathered, supervised
double data entry, and analyzed the data, and vouch for the
completeness and accuracy of the data and analysis. All
research personnel and statisticians were blinded throughout
the study, including initial review of all data. The industry
authors provided technical expertise related to the protocol,
clinical supplies, and logistics, made observations through-
out the study, helped review blinded data, and participated
in manuscript preparation. PI and non-sponsor authors have
full legal ability to publish any findings.
References
Agarwal KN, Bhasin SK (2002). Feasibility studies to control acute
diarrhoea in children by feeding fermented milk preparations
Actimel and Indian Dahi. Eur J Clin Nutr 56 (Suppl 4), S56–S59.
Baba N, Samson S, Bourdet-Sicard R, Rubio M, Sarfati M (2009).
Selected commensal-related bacteria and toll-like receptor 3
agonist combinatorial codes synergistically induce interleukin-12
production by dendritic cells to trigger a T helper type 1 polarizing
programme. Immunology 128, e523–e531.
Cordell RL, MacDonald JK, Solomon SL, Jackson LA, Boase J (1997).
Illnesses and absence due to illness among children attending
child care facilities in Seattle-King County, Washington. Pediatrics
100, 850–855.
Dales R, Cakmak S, Brand K, Judek S (2004). Respiratory illness in
children attending daycare. Pediatric Pulmonology 38, 6409.
de Moreno de LeBlanc A, Chaves S, Carmuega E, Weill R, Antoine J,
Perdigon G (2008). Effect of long-term continuous consumption
of fermented milk containing probiotic bacteria on mucosal
The DRINK study
D Merenstein et al
676
European Journal of Clinical Nutritionimmunity and the activity of peritoneal macrophages.
Immunobiology 213, 97–108.
Djouzi Z, Andrieux C, Degivry MC, Bouley C, Szylit O (1997). The
association of yogurt starters with Lactobacillus casei DN 114.001
in fermented milk alters the composition and metabolism of
intestinal microflora in germ-free rats and in human flora-
associated rats. J Nutr 127, 2260–2266.
Feeney A, North F, Head J, Canner R, Marmot M (1998). Socio-
economic and sex differentials in reason for sickness absence from
the Whitehall II Study. Occup Environ Med 55, 91–98.
Fleming DW, Cochi SL, Hightower AW, Broome CV (1987). Child-
hood upper respiratory tract infections: to what degree is
incidence affected by day-care attendance? Pediatrics 79, 55–60.
Fleming TR, DeMets DL (1996). Surrogate end points in clinical trials:
are we being misled? Ann Intern Med 125, 605–613.
Food and Agriculture Organization of the United Nations and World
Health Organization (2001). Health and nutritional properties of
probiotics in food including powder milk with live lactic acid
bacteria. Report of a Joint FAO/WHO Expert Consultation on
Evaluation of Health and Nutritional Properties of Probiotics in
Food Including Powder Milk with Live Lactic Acid Bacteria.
Co ´rdoba, Argentina, 1–4 October 2001.
Freitas M, Tavan E, Cayuela C, Diop L, Sapin C, Trugnan G (2003).
Host-pathogens cross-talk. Indigenous bacteria and probiotics also
play the game. Biol Cell 95, 503–506.
Giovannini M, Agostoni C, Riva E, Salvini F, Ruscitto A, Zuccotti GV
et al. (2007). A randomized prospective double blind controlled
trial on effects of long-term consumption of fermented milk
containing Lactobacillus casei in pre-school children with allergic
asthma and/or rhinitis. Pediatr Res 62, 215–220.
Glasgow RE, Magid DJ, Beck A, Ritzwoller D, Estabrooks PA (2005).
Practical clinical trials for translating research to practice: design
and measurement recommendations. Med Care 43, 551–557.
Greenberg SB (2002). Respiratory viral infections in adults. Curr Opin
Pulm Med 8, 201–208.
Guerin-Danan C, Chabanet C, Pedone C, Popot F, Vaissade P, Bouley
C et al. (1998). Milk fermented with yogurt cultures and
Lactobacillus casei compared with yogurt and gelled milk:
influence on intestinal microflora in healthy infants. Am J Clin
Nutr 67, 111–117.
Guerin-Danan C, Meslin JC, Chambard A, Charpilienne A, Relano P,
Bouley C et al. (2001). Food supplementation with milk fermented
by Lactobacillus casei DN-114 001 protects suckling rats from
rotavirus-associated diarrhea. J Nutr 131, 111–117.
Guillemard E, Tondu F, Lacoin F, Schrezenmeir J (2010). Consump-
tion of a fermented dairy product containing the probiotic
Lactobacillus casei DN-114001 reduces the duration of respiratory
infections in the elderly in a randomised controlled trial. Br J Nutr
103, 58–68.
Haskins R (1989). Acute illness in day care: how much does it cost?
Bull N Y Acad Med 65, 319–343.
Hatakka K, Savilahti E, Ponka A, Meurman JH, Poussa T, Nase L et al.
(2001). Effect of long term consumption of probiotic milk on
infections in children attending day care centres: double blind,
randomised trial. BMJ 322, 1327.
Hickson M, D’Souza AL, Muthu N, Rogers TR, Want S, Rajkumar C
et al. (2007). Use of probiotic Lactobacillus preparation to prevent
diarrhoea associated with antibiotics: randomised double blind
placebo controlled trial. BMJ 335,8 0 .
Ingrassia I, Leplingard A, Darfeuille-Michaud A (2005). Lactobacillus
casei DN-114 001 inhibits the ability of adherent-invasive
Escherichia coli isolated from Crohn’s disease patients to adhere
to and to invade intestinal epithelial cells. Appl Environ Microbiol
71, 2880–2887.
Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri
E (2001). Probiotics in primary prevention of atopic disease: a
randomised placebo-controlled trial. Lancet 357, 1076–1079.
Lin HC, Su BH, Chen AC, Lin TW, Tsai CH, Yeh TF et al. (2005). Oral
probiotics reduce the incidence and severity of necrotizing
enterocolitis in very low birth weight infants. Pediatrics 115,
1–4.
Lin JS, Chiu YH, Lin NT, Chu CH, Huang KC, Liao KW et al. (2009).
Different effects of probiotic species/strains on infections in
preschool children: a double-blind, randomized, controlled study.
Vaccine 27, 1073–1079.
Mastrandrea F, Coradduzza G, Serio G, Minardi A, Manelli M,
Ardito S et al. (2004). Probiotics reduce the CD34þ hemopoietic
precursor cell increased traffic in allergic subjects. Allerg Immunol
(Paris) 36, 118–122.
Medici M, Vinderola CG, Weill R, Perdigon G (2005). Effect of fermented
milk containing probiotic bacteria in the prevention of an enter-
oinvasive Escherichia coli infection in mice. J Dairy Res 72, 243–249.
Oozeer R, Goupil-Feuillerat N, Alpert CA, van de Guchte M, Anba J,
Mengaud J et al. (2002). Lactobacillus casei is able to survive and
initiate protein synthesis during its transit in the digestive tract of
human flora-associated mice. Appl Environ Microbiol 68, 3570–3574.
Oozeer R, Leplingard A, Mater DD, Mogenet A, Michelin R, Seksek I
et al. (2006). Survival of Lactobacillus casei in the human digestive
tract after consumption of fermented milk. Appl Environ Microbiol
72, 5615–5617.
Parassol N, Freitas M, Thoreux K, Dalmasso G, Bourdet-Sicard R,
Rampal P (2005). Lactobacillus casei DN-114 001 inhibits the
increase in paracellular permeability of enteropathogenic Escher-
ichia coli-infected T84 cells. Res Microbiol 156, 256–262.
Pedone CA, Bernabeu AO, Postaire ER, Bouley CF, Reinert P (1999).
The effect of supplementation with milk fermented by Lactoba-
cillus casei (strain DN-114 001) on acute diarrhoea in children
attending day care centres. Int J Clin Pract 53, 179–184.
Pedone CA, Arnaud CC, Postaire ER, Bouley CF, Reinert P (2000).
Multicentric study of the effect of milk fermented by Lactobacillus
casei on the incidence of diarrhoea. Int J Clin Pract 54, 568–571.
Rochet V, Rigottier-Gois L, Levenez F, Cadiou J, Marteau P, Bresson JL
et al. (2008). Modulation of Lactobacillus casei in ileal and fecal
samples from healthy volunteers after consumption of a fermen-
ted milk containing Lactobacillus casei DN-114 001Rif. Can J
Microbiol 54, 660–667.
Rosenfeldt V, Michaelsen KF, Jakobsen M, Larsen CN, Moller PL,
Tvede M et al. (2002). Effect of probiotic Lactobacillus strains on
acute diarrhea in a cohort of nonhospitalized children attending
day-care centers. Pediatr Infect Dis J 21, 417–419.
Shaughnessy AF, Slawson DC (1997). POEMs: patient-oriented
evidence that matters. Ann Intern Med 126, 667.
Shaughnessy AF, Slawson DC (2003). What happened to the valid
POEMs? A survey of review articles on the treatment of type 2
diabetes. BMJ 327, 266.
Silverstein M, Sales AE, Koepsell TD (2003). Health care utilization
and expenditures associated with child care attendance: a
nationally representative sample. Pediatrics 111, e371–e375.
Tien MT, Girardin SE, Regnault B, Le Bourhis L, Dillies MA, Coppee JY
et al. (2006). Anti-inflammatory effect of Lactobacillus casei on
Shigella-infected human intestinal epithelial cells. J Immunol 176,
1228–1237.
Tunis SR, Stryer DB, Clancy CM (2003). Practical clinical trials:
increasing the value of clinical research for decision making in
clinical and health policy. JAMA 290, 1624–1632.
Vanderhoof JA, Whitney DB, Antonson DL, Hanner TL, Lupo JV,
Young RJ (1999). Lactobacillus GG in the prevention of antibiotic-
associated diarrhea in children. J Pediatr 135, 564–568.
Weizman Z, Asli G, Alsheikh A (2005). Effect of a probiotic infant
formula on infections in child care centers: comparison of two
probiotic agents. Pediatrics 115, 5–9.
This work is licensed under the Creative
Commons Attribution-NonCommercial-No
Derivative Works 3.0 Unported License. To view a copy of
this license, visit http://creativecommons.org/licenses/
by-nc-nd/3.0/
The DRINK study
D Merenstein et al
677
European Journal of Clinical Nutrition